Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Squalamine Lactate for Neovascular AMD
2005-001235-30Phase 3Active
- Sponsor
- Genaera Corporation
- Start
- Sep 2005
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of squalamine in age-related macular degeneration (AMD) (3 arms), sponsored by Genaera Corporation. Primary endpoint: Loss of best corrected visual acuity (BCVA) ≥ 15 letters at week 52. Started Sep 2005; status: active.
02
Drugs
squalamine
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2005-001235-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001235-30.